Contents

Search

elapegademase (Revcovi)

Indications: - treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric & adult patients Dosage: - 1.5 mL of 1.6 mg/mL Injection [Revcovi] Laboratory: - adjust dose gradually down to maintain trough ADA activity >30 mmol/hr/L, trough dAXP level <0.02 mmol/L, &/or to maintain adequate immune reconstitution based on clinical assessment Mechanism of action: - PEGylated recombinant adenosine deaminase

General

metabolic agent (metabolic modifier)

Database Correlations

PUBCHEM cid=121488177

References

  1. RxNorm
  2. PubChem: 121488177
  3. FDA Approves Elapegademase for Treatment of ADA-SCID in Pediatric and Adult Patients Rare Disease Report. Oct 5, 2018 https://www.raredr.com/news/fda-approves-elapegademase-treatment-adascid-in-pediatric-adult-patients
  4. elapegademase (Rx) Medscape https://reference.medscape.com/drug/revcovi-elapegademase-1000300